comparemela.com
Home
Live Updates
TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively : comparemela.com
TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively
/PRNewswire/ -- Johnson & Johnson announced today updated results from an open-label, multicenter, multi-cohort Phase 1 study of the safety and efficacy of...
Related Keywords
San Antonio ,
Texas ,
United States ,
Barcelona ,
Comunidad Autonoma De Cataluna ,
Spain ,
Vilaseca ,
American ,
Prnewswire Johnson ,
Sabine Brookman ,
Rodriguez Faba ,
Ania Diantonio ,
Indianj Urol ,
American Cancer Society ,
American Urological Association ,
Janssen Pharmaceuticals ,
Johnson ,
Janssen Research Development ,
Drug Administration ,
Astex Pharmaceuticals ,
Late Development Oncology ,
European Association Of Urology ,
Bladder Cancer Advocacy Network ,
European Society For Medical Oncology ,
Exchange Commission ,
None Of Janssen Research Development ,
Janssen Biotech Inc ,
Oral Presentation Session ,
Urological Association ,
Annual Meeting ,
Bacillus Calmette Gu ,
European Society ,
Medical Oncology ,
European Association ,
Antoni Vilaseca ,
Sabine Brookman May ,
Vice President ,
Johnson Innovative ,
Breakthrough Therapy Designation ,
European Medicines Agency ,
Soft Tissue Mineralization ,
Embryo Fetal Toxicity ,
High Risk Non ,
Muscle Invasive Bladder Cancer ,
Innovative Medicine ,
Janssen Research ,
Janssen Biotech ,
Private Securities Litigation Reform Act ,
Annual Report ,
Note Regarding Forward Looking ,
Quarterly Reports ,
Urology Young Academic Urologists ,
Urol Assoc ,
Bladder Cancer Advocacy ,
Accessed April ,
Johnson Amp ,
comparemela.com © 2020. All Rights Reserved.